EORTC PhD fellow Emma Willems addresses how do leaders of international non-profit organizations deal with resource pressures caused by the COVID-19 pandemic

Since 1991, the EORTC Fellowship Program enables physicians, statisticians and scientists from around the world to engage in clinical research that advances the EORTC’s evolving scientific strategy in the fight against cancer. Support for the EORTC Fellowship Programme comes from several sources, and more than 190 fellowships covering 35 countries have been awarded so far.

Emma L. Willems, a PhD fellow at EORTC funded by the EORTC’s Cancer Research Fund (ECRF), has co-authored an article that was recently published in the Journal of Contingencies and Crisis Management.

In their article, Emma L. Willems, Stijn Van Puyvelde, Marc Jegers and Peter Raeymaeckers overview the challenges experienced by international non-profits during the COVID-19 pandemic and investigate the responsive actions of the leadership (board of directors and managerial executive) to the health crisis. The results indicate resource decreases in nearly all stakeholder channels. In response, non-profit boards increased activity levels by mainly focusing on adapting organizational offerings and increasing support to the organization. Managerial executives also increased their activity levels, by focusing on safeguarding financial stability, planning and adapting operations to confinement measures.

You can read the full article here.

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023